Mer­ck­'s Keytru­da nets an­oth­er ap­proval, this time in triple neg­a­tive breast can­cer. Can it catch up to Tecen­triq?

An­oth­er day, an­oth­er win for Mer­ck’s block­buster Keytru­da.

The FDA has grant­ed ac­cel­er­at­ed ap­proval for the cash cow com­bined with chemother­a­py in triple neg­a­tive breast can­cer, giv­ing the drug the green light in its 18th dif­fer­ent can­cer. Mon­day’s new in­di­ca­tion comes for pa­tients with PD-L1-ex­press­ing tu­mors with a Com­bined Pos­i­tive Score of at least 10.

Mer­ck not­ed that due to the na­ture of the ac­cel­er­at­ed ap­proval, the thumbs up is con­tin­gent up­on con­fir­ma­to­ry tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER